Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note

07.10.25 00:15 Uhr

Werte in diesem Artikel
Aktien

1.344,00 JPY 71,00 JPY 5,58%

7,36 EUR 0,04 EUR 0,55%

In the latest trading session, Teladoc (TDOC) closed at $8.57, marking a -4.88% move from the previous day. This change lagged the S&P 500's daily gain of 0.37%. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, added 0.71%. Shares of the telehealth services provider witnessed a gain of 15.22% over the previous month, beating the performance of the Medical sector with its gain of 5.9%, and the S&P 500's gain of 4.26%.The investment community will be paying close attention to the earnings performance of Teladoc in its upcoming release. On that day, Teladoc is projected to report earnings of -$0.26 per share, which would represent a year-over-year decline of 36.84%. In the meantime, our current consensus estimate forecasts the revenue to be $625.56 million, indicating a 2.33% decline compared to the corresponding quarter of the prior year. TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$1.17 per share and revenue of $2.52 billion. These results would represent year-over-year changes of +80.07% and -1.82%, respectively. Investors should also note any recent changes to analyst estimates for Teladoc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Teladoc presently features a Zacks Rank of #2 (Buy). The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 143, placing it within the bottom 43% of over 250 industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Teladoc und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf note

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf note

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Teladoc Inc

Wer­bung

Analysen zu Teladoc Inc

DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
15.03.2018Teladoc HoldDeutsche Bank AG
28.02.2018Teladoc BuyChardan Capital Markets
DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
28.02.2018Teladoc BuyChardan Capital Markets
08.12.2017Teladoc BuyDeutsche Bank AG
DatumRatingAnalyst
15.03.2018Teladoc HoldDeutsche Bank AG
18.09.2017Teladoc NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teladoc Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen